Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Seres Therapeutics, Inc. (“Seres” or the “Company”) (Nasdaq: MCRB) concerning possible violations of federal securities laws.

If you purchased shares of Seres and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The investigation concerns events surrounding the Company’s announcement on July 29, 2016 that its Phase 2 clinical study for ECOSPOR™ did not meet its primary endpoint of reducing the relative risk of Clostridium difficile infection recurrence. When this news was released, shares of Seres dropped in value sharply. Two days before the announcement, however, the Company’s President, CEO and Chairman of the Board sold 20,000 shares of Seres at a much higher price.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160805005690/en/